tetano
Editor, Senior Moderator
Pediatrics
. 2023 Jul 21;e2022060351.
doi: 10.1542/peds.2022-060351. Online ahead of print. A Systematic Review of Persistent Clinical Features After SARS-CoV-2 in the Pediatric Population
Li Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Xuan Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Jia Nie[SUP] 3 [/SUP], Kun Tang[SUP] 2 [/SUP], Zulfiqar A Bhutta[SUP] 1 4 5 [/SUP]
Affiliations
Context: Long-term health effects after coronavirus disease 2019 (COVID-19) have been increasingly reported but their prevalence and significance in the pediatric population remains uncertain.
Objective: To present the prevalence and characteristics of the long-term clinical features of COVID-19 (long COVID) in the global pediatric population.
Data sources: PubMed, Embase, Web of Science, Cochrane Library, WHO COVID-19 database, google scholar, medRxiv, bioRxiv, and multiple national public health databases.
Study selection: Published articles and preprints from December, 2019 to December, 2022 investigating the epidemiology and characteristics of persistent clinical features at least 3 months after COVID-19 in children and adolescents (0-19 years old) were included.
Data extraction: Study characteristics and detailed description of long COVID were extracted into a predefined form.
Results: Twenty seven cohorts and 4 cross-sectional studies met the inclusion criteria and involved over 15 000 pediatric participants. A total of more than 20 persistent symptoms and clinical features were reported among children and adolescents. 16.2% (95% confidence interval 8.5% to 28.6%) of the pediatric participants experienced 1 or more persistent symptom(s) at least 3 months post COVID-19. Female gender might be associated with developing certain long COVID symptoms.
Limitations: Included studies presented with great heterogeneity because of significant variations in the definition of "long COVID," follow up duration, and method. There could be nonresponse and other potential bias.
Conclusions: Persistent clinical features beyond 3 months among children and adolescents with proven COVID-19 are common and the symptom spectrum is wide. High-quality, prospective studies with proper controls are necessary in the future.
. 2023 Jul 21;e2022060351.
doi: 10.1542/peds.2022-060351. Online ahead of print. A Systematic Review of Persistent Clinical Features After SARS-CoV-2 in the Pediatric Population
Li Jiang[SUP] #[/SUP][SUP] 1 [/SUP], Xuan Li[SUP] #[/SUP][SUP] 1 2 [/SUP], Jia Nie[SUP] 3 [/SUP], Kun Tang[SUP] 2 [/SUP], Zulfiqar A Bhutta[SUP] 1 4 5 [/SUP]
Affiliations
- PMID: 37476923
- DOI: 10.1542/peds.2022-060351
Context: Long-term health effects after coronavirus disease 2019 (COVID-19) have been increasingly reported but their prevalence and significance in the pediatric population remains uncertain.
Objective: To present the prevalence and characteristics of the long-term clinical features of COVID-19 (long COVID) in the global pediatric population.
Data sources: PubMed, Embase, Web of Science, Cochrane Library, WHO COVID-19 database, google scholar, medRxiv, bioRxiv, and multiple national public health databases.
Study selection: Published articles and preprints from December, 2019 to December, 2022 investigating the epidemiology and characteristics of persistent clinical features at least 3 months after COVID-19 in children and adolescents (0-19 years old) were included.
Data extraction: Study characteristics and detailed description of long COVID were extracted into a predefined form.
Results: Twenty seven cohorts and 4 cross-sectional studies met the inclusion criteria and involved over 15 000 pediatric participants. A total of more than 20 persistent symptoms and clinical features were reported among children and adolescents. 16.2% (95% confidence interval 8.5% to 28.6%) of the pediatric participants experienced 1 or more persistent symptom(s) at least 3 months post COVID-19. Female gender might be associated with developing certain long COVID symptoms.
Limitations: Included studies presented with great heterogeneity because of significant variations in the definition of "long COVID," follow up duration, and method. There could be nonresponse and other potential bias.
Conclusions: Persistent clinical features beyond 3 months among children and adolescents with proven COVID-19 are common and the symptom spectrum is wide. High-quality, prospective studies with proper controls are necessary in the future.